181 related articles for article (PubMed ID: 34407349)
1. Lorlatinib in a Child with
Bagchi A; Orr BA; Campagne O; Dhanda S; Nair S; Tran Q; Christensen AM; Gajjar A; Furtado LV; Vasilyeva A; Boop F; Stewart C; Robinson GW
N Engl J Med; 2021 Aug; 385(8):761-763. PubMed ID: 34407349
[No Abstract] [Full Text] [Related]
2. An Infant-Type Hemispheric Glioma With SOX5::ALK: A Novel Fusion.
Tsai CC; Huang MH; Fang CL; Hsieh KL; Hsieh TH; Ho WL; Chang H; Tsai ML; Kao YC; Miser JS; Wong TT; Su MY; Liu YL
J Natl Compr Canc Netw; 2024 Feb; 22(1):. PubMed ID: 38394779
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological and clinical properties of lorlatinib in the treatment of
El Darsa H; Abdel-Rahman O; Sangha R
Expert Opin Pharmacother; 2020 Sep; 21(13):1547-1554. PubMed ID: 32511029
[TBL] [Abstract][Full Text] [Related]
4.
Shaw AT; Solomon BJ; Besse B; Bauer TM; Lin CC; Soo RA; Riely GJ; Ou SI; Clancy JS; Li S; Abbattista A; Thurm H; Satouchi M; Camidge DR; Kao S; Chiari R; Gadgeel SM; Felip E; Martini JF
J Clin Oncol; 2019 Jun; 37(16):1370-1379. PubMed ID: 30892989
[TBL] [Abstract][Full Text] [Related]
5. Successful application of lorlatinib in a 23-year-old patient with anaplastic lymphoma kinase (ALK)-positive lung cancer and multiple brain metastases.
Murakami Y; Kawashima Y; Chiba S; Hara S; Yamazaki Y; Doman T; Saito S; Odaka T; Ogasawara T; Shimizu H; Sugisaka J; Aiba T; Toi Y; Yamanda S; Kimura Y; Sugawara S
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1981. PubMed ID: 38212894
[TBL] [Abstract][Full Text] [Related]
6. Rapid regression of neurological symptoms in patients with metastasised ALK+ lung cancer who are treated with lorlatinib: a report of two cases.
Gafer H; de Waard Q; Compter A; van den Heuvel M
BMJ Case Rep; 2019 Jul; 12(7):. PubMed ID: 31345828
[TBL] [Abstract][Full Text] [Related]
7. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
8. Lorlatinib as a treatment for ALK-positive lung cancer.
Baba K; Goto Y
Future Oncol; 2022 Aug; 18(24):2745-2766. PubMed ID: 35787143
[TBL] [Abstract][Full Text] [Related]
9. Lorlatinib for ALK-fused, infant-type hemispheric glioma with lung metastasis: a case report.
Lai M; Li S; Li H; Hu Q; Li J; Zhou J; Ai R; Zhen J; Zhou Z; Wang L; Zhang Y; Hu W; Yuan L; Ma X; Zhang X; Song C; Li Z; Cai L
Ann Clin Transl Neurol; 2023 May; 10(5):836-841. PubMed ID: 37000961
[TBL] [Abstract][Full Text] [Related]
10. Intracranial remission with brigatinib rechallenge as fifth-line ALK inhibition therapy in a lung cancer patient.
Hochmair M; Weinlinger C; Prosch H
Anticancer Drugs; 2019 Nov; 30(10):1058-1060. PubMed ID: 31033499
[TBL] [Abstract][Full Text] [Related]
11. Unusual high-grade and low-grade glioma in an infant with PPP1CB-ALK gene fusion.
Ng A; Levy ML; Malicki DM; Crawford JR
BMJ Case Rep; 2019 Feb; 12(2):. PubMed ID: 30709888
[No Abstract] [Full Text] [Related]
12. Second temporal remission in a malignant glioma with trofosfamide and etoposide: a case report.
Wolff JE; Boos J; Krähling KH; Jürgens H
Klin Padiatr; 1996; 208(4):190-2. PubMed ID: 8776706
[TBL] [Abstract][Full Text] [Related]
13. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
Baldacci S; Besse B; Avrillon V; Mennecier B; Mazieres J; Dubray-Longeras P; Cortot AB; Descourt R; Doubre H; Quantin X; Duruisseaux M; Monnet I; Moro-Sibilot D; Cadranel J; Clément-Duchêne C; Cousin S; Ricordel C; Merle P; Otto J; Schneider S; Langlais A; Morin F; Westeel V; Girard N
Eur J Cancer; 2022 May; 166():51-59. PubMed ID: 35278825
[TBL] [Abstract][Full Text] [Related]
14. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
Naito T; Shiraishi H; Fujiwara Y
Jpn J Clin Oncol; 2021 Jan; 51(1):37-44. PubMed ID: 33147606
[TBL] [Abstract][Full Text] [Related]
15. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
Yang J; Gong W
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):173-178. PubMed ID: 30657349
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma.
Suk Y; Singh SK
Cell Rep Med; 2023 Jun; 4(6):101071. PubMed ID: 37343514
[TBL] [Abstract][Full Text] [Related]
17. Lorlatinib for the Treatment of ALK Fusion-Positive Infant-Type Hemispheric Glioma: A Case Report.
Greenwell AM; Baughan S; Altinok D; Marupudi NI; Kupsky W; Kumar-Sinha C; Gorsi HS
JCO Precis Oncol; 2022 Oct; 6():e2200255. PubMed ID: 36315913
[No Abstract] [Full Text] [Related]
18. Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed
Liu T; Merguerian MD; Rowe SP; Pratilas CA; Chen AR; Ladle BH
Cold Spring Harb Mol Case Stud; 2021 Aug; 7(4):. PubMed ID: 34210658
[TBL] [Abstract][Full Text] [Related]
19. Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report.
Hu J; Zhang B; Yao F; Fu Y; Chen D; Li D; Du N; Lizaso A; Song J; Zhang L; Li X
Ther Adv Respir Dis; 2020; 14():1753466620935770. PubMed ID: 32600123
[No Abstract] [Full Text] [Related]
20. Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK -rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report.
Jin C; He Z; Guo M; Liu S; Wang Y; Qiu J; Li C; Wu D
Anticancer Drugs; 2022 Aug; 33(7):696-700. PubMed ID: 35324529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
